Karyopharm Therapeutics Inc (KPTI.OQ)
19 Sep 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|46||2017||President, Co-Founder, Chief Scientific Officer|
|54||Co-Founder, Chief Executive Officer and Director|
|59||2017||Chief Financial Officer, Executive Vice President, Treasurer|
|37||2017||Executive Vice President, Chief Business Officer, General Counsel and Secretary|
|50||2018||Executive Vice President, Chief Commercial Officer|
- BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78
- BRIEF-Karyopharm Therapeutics Announces Closing Of Public Offering Of Common Stock And Exercise In Full Of Underwriters’ Option To Purchase Additional Shares
- BRIEF-Karyopharm Therapeutics Says Offering Shares Of Common Stock With Aggregate Offering Price Of $125 Mln
- BRIEF-Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
- BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma